Journal Article Review Epublish
PubMed: 40229816 DOI: 10.1186/s12950-025-00432-2
Mucosal immunotherapy targeting APC in lung disease.
J Inflamm (Lond) 22(1):15
Authors: Yangqi Liu, Zijian Chen, Hanchang Cheng, Runzhi Zheng, Weizhe Huang
Affiliations
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
Abstract
Several studies have demonstrated that the pulmonary immune response is primarily facilitated by antigen-presenting cells (APCs), and that both professional and non-professional APCs contribute to overall pulmonary immunity. APCs play unique roles and mechanisms in pathogen elimination and immunomodulation. Mucosal immunity exhibits potential advantages over traditional parenteral immunity in that it stimulates immune defenses in mucosal and systemic tissues, which is important for reducing the burden of lung disease. However, obtaining a comprehensive understanding of the crosstalk between mucosal immunity and APC in the context of various lung diseases remains challenging. This mini-review aimed to elucidate the mechanisms of novel mucosal immunity, targeting APC action during lung infections, allergies, and malignant tumorigenesis. This minreview provides important insights into more effective therapeutic approaches for various lung diseases.
MeSH
Lung, Immunotherapy, Immunity, Mucosal, Immunity, Genes, Apc, Lung Diseases